WHAT IS CLAIMED IS:

Claim 1. A method of attenuating the post-translational fucosylation of a human IgG Fc region, ~~which comprises~~ comprising:

(A) modifying a human IgG~~said~~ Fc region to comprise an amino acid substitution ~~at position: L234, L235, F243, R292, Y300, V305, or P396,~~ relative to a wild-type Fc region to yield a modified Fc region;

(B) assessing whether said modified Fc region exhibits a ratio of high mannose oligosaccharide glycosylation to complex oligosaccharide glycosylation that is greater than 0.2;

(C) selecting said modified Fc region if said modified Fc region exhibits said ratio that is greater than 0.2;and

~~(A)~~(D) expressing said selected modified Fc region in a host cell capable of mediating normal glycosylation.

Claim 2. The method of claim 1, wherein said ~~Fc region comprises an~~ amino acid substitution is at position L234, L235, F243, R292, Y300, V305 or P396.

Claim 3. The method of claim 2, wherein:

(a) said substitution at position F243 is F243C, F243L or F243R;

(b) said substitution at position R292 is R292G, R292L, R292M, R292P, R292S or R292Y;

(c) said substitution at position Y300 is Y300L; or

(d) said substitution at position P396 is P396L.

Claim 4. The method of claim 2, wherein said amino acid substitutions comprise substitutions at positions L234 and L235.

Claim 5. The method of claim 4, wherein said amino acid substitutions comprise L234F and L235V.

Claim 46. The method of any one of claims 1-~~3~~5, wherein said selected modified Fc region exhibits altered affinity to a CD16A receptor, a CD16B receptor, a CD32B receptor or a CD32A receptor.

Claim ~~57~~. The method of claim ~~46~~, wherein said selected modified Fc region exhibits decreased affinity to a CD32B receptor.

Claim ~~68~~. The method of claim ~~46~~, wherein said selected modified Fc region exhibits increased affinity to a CD16A receptor.

Claim ~~79~~. The method of any one of claims 1-~~68~~, wherein said selected modified Fc region is the Fc region of a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody or a single chain antibody.

Claim ~~810~~. The method of claim ~~79~~, wherein said antibody specifically binds CD16A, CD32B, HER2/neu, A33, CD5, CD11c, CD19, CD20, CD22, CD23, CD27, CD40, CD45, CD79a, CD79b, CD103, CTLA4, ErbB1, ErbB3, ErbB4, VEGF receptor, TNF-α receptor, TNF-ß receptor, or TNF-γ receptor~~CD16A~~.

Claim ~~911~~. The method of claim ~~79~~, wherein said antibody specifically binds a cancer antigen associated with cancer.

Claim ~~10~~12. The method of claim ~~9~~11, wherein said cancer is a breast, ovarian, prostate, cervical, lung or pancreatic cancer.

Claim ~~11~~13. The method of claim ~~9~~11, wherein said cancer is breast cancer and said antigen is HER2/neu.

~~Claim 12. An antibody that specifically binds a cancer antigen characteristic of a cancer selected from the group consisting of breast, ovarian, prostate, cervical, lung or pancreatic cancer wherein said antibody comprises an Fc region produced through the method of any one of claims 1-8.~~

~~Claim 13. A polypeptide comprising a variant human IgG Fc region, wherein said Fc region comprises:~~

~~(A) an amino acid substitution at position: L234, L235, F243, R292, Y300, V305, or P396, and~~

~~(B) a ratio of high manose oligosaccharide glycosylation to complex oligosaccharide glycosylation that is greater than 0.2.~~

Claim 14. ~~The polypeptide of claim 13, wherein said Fc region comprises an amino acid substitution an position F243, R292, Y300 or P396.~~ The method of claim 1, wherein said ratio is: Σ (% Man5 + % Man6 + % Man7 + % Man8 + % Man9) : Σ (% G0F + % G1F + % G2F).

~~Claim 15. The polypeptide of claim 14, wherein:~~

~~(a) said substitution at position F243 is F243C, F243L or F243R;~~

~~(b) said substitution at position R292 is R292G, R292L, R292M, R292P, R292S or R292Y;~~

~~(c) said substitution at position Y300 is Y300L;~~

~~(d) said substitution at position P396 is P396L.~~

~~Claim 16. The polypeptide of claim 13, wherein said Fc region exhibits altered affinity to a CD16A receptor, a CD16B receptor, a CD32B receptor or a CD32A receptor.~~

~~Claim 17. The polypeptide of claim 16, wherein said Fc region exhibits decreased affinity to a CD32B receptor.~~

~~Claim 18. The polypeptide of claim 16, wherein said Fc region exhibits increased affinity to a CD16A receptor.~~

~~Claim 19. The antibody of claim 12 or the polypeptide of any one of claims 13-18, wherein said Fc region is the Fc region of a monoclonal antibody, a~~

~~chimeric antibody, a humanized antibody, a human antibody or a single chain antibody.~~

~~Claim 20. The antibody of claim 12 or the polypeptide of claim 19, wherein said antibody specifically binds CD16A, CD32B, HER2/neu, A33, CD5, CD11c, CD19, CD20, CD22, CD23, CD27, CD40, CD45, CD79a, CD79b, CD103, CTLA4, ErbB1, ErbB3, ErbB4, VEGF receptor, TNF-α receptor, TNF-ß receptor, or TNF-γ receptorCD16A.~~

~~Claim 21. The antibody of claim 12 or the polypeptide of claim 19, wherein said antibody or said polypeptide specifically binds a cancer antigen associated with a cancer.~~

~~Claim 22. The antibody of claim 12 or the polypeptide of claim 21, wherein said cancer is a breast, ovarian, prostate, cervical, lung or pancreatic cancer.~~

~~Claim 23. The antibody or the polypeptide of claim 22, wherein said cancer is breast cancer and said antigen is HER2/neu.~~

Claim ~~24~~15. The use of an antibody comprising an Fc region produced by the method of any one of claims 1-14 ~~use of the polypeptide of any one of claims 13-23~~ in the manufacture of a medicament for treating a disease in a subject in need thereof.

Claim ~~25~~16. The use of an antibody comprising an Fc region produced by the method of any one of claims 1-14~~method of any one of claims 1-14 for use of the polypeptide of any one of claims 13-23~~ in the manufacture of a medicament for treating a cancer characterized by a cancer antigen in a subject in need thereof.

Claim ~~26~~17. The use of claim ~~25~~16, wherein said cancer is breast cancer and said antigen is HER-2/neu.

~~Claim 27. A pharmaceutical composition comprising a therapeutically effective amount of the polypeptide of any one of claims 13-18, and a pharmaceutically acceptable carrier.~~

~~Claim 28. A pharmaceutical composition comprising a therapeutically effective amount of the antibody of claim 12, or the antibody or polypeptide of any one of claims 19-23, and a pharmaceutically acceptable carrier~~.